Loading stock data…
SRRK
$46.48+0.11 (+0.24%)
Market ClosedLast close May 4
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Scholar Rock Holding Corporation in the Healthcare sector is trading at $46.48. The stock is currently 10% below its 52-week high of $51.62, remaining 15.7% above its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why SRRK maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$46.48
Potential Upside
5%
Whystock Fair Value$48.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$57.73+24.2%
Range$48.00 – $70.00
Fundamentals
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-153.95%
Volume
Today's trading volume
1.02M
Recent News
Scholar Rock (SRRK) Deepens SMA Manufacturing Footprint: Strategic Resilience Move or Regulatory Risk Signal?
On March 31, 2026, Scholar Rock announced it had resubmitted its Biologics License Application to the FDA for apitegromab in spinal muscular atrophy, now incorporating both the Novo Nordisk-owned Catalent Indiana site and a second U.S.-based fill-finish facility in line with recent FDA guidance. An interesting angle is that the original Complete Response Letter focused solely on third-party manufacturing observations, so this dual-facility resubmission directly addresses supply-chain...
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept.
Scholar Rock (NASDAQ:SRRK) said it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration for apitegromab as a treatment for children and adults with spinal muscular atrophy (SMA), positioning the company for a new review cycle and a potential regulatory dec
Correction: Sector Update: Health Care Stocks Advance Premarket Tuesday
(Corrects the upfront cash consideration in the second paragraph to $6.3 billion.) Health care st
Sector Update: Health Care Stocks Advance Premarket Tuesday
Health care stocks were advancing premarket Tuesday, with the State Street Health Care Select Sector